How long do you continue a first-line somatostatin receptor ligand before concluding inadequate biochemical response and escalating therapy in a patient with persistent acromegaly after transsphenoidal surgery?

First-generation somatostatin receptor ligands (SRLs) are often used as first-line therapy for patients with persistent acromegaly after surgery. Several factors can predict biochemical responses to such therapy, including older age, lower baseline insulin-like growth factor I (IGF-I), paradoxical g...